Skip to main content

Table 3 Univariate and multivariate prognostic factor for longer PFS in angiosarcoma patients treated with weekly paclitaxel plus or minus bevacizumab a

From: Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial

Parameters

Univariate analysis

Multivariate analysisc

HRb (95% CI)

p

HRb (95% CI)

p

Clinical characteristics

 Location

Superficial

1

  

1

  

Visceral

1.89

(0.97–3.65)

0.055

1.53

(0.73–3.23)

0.26

 Medical history

Radiation-induced

1

  

1

  

De novo

2.21

(1.13–4.30)

0.017

2.49

(1.13–5.50)

0.024

Baseline biomarkers

 Human FGF (pg/mL)

0.96

(0.86–1.07)

0.48

–

  

 PlGF (pg/mL)

1.03

(1.00–1.05)

0.037

1.02

(0.99–1.04)

0.17

 SCF sR/c-kit (ng/mL)

0.99

(0.87–1.13)

0.86

–

  

 sE-Selectin (ng/mL)

1.00

(0.98–1.01)

0.85

–

  

 TSP-1 (μg/mL)

0.99

(0.97–1.01)

0.25

–

  

 VEGF (ng/mL)

0.70

(0.25–1.96)

0.49

–

  

 VEGF-C (ng/mL)

0.75

(0.60–0.95)

0.015

0.69

(0.54–0.88)

0.003

  1. aConsidering the absence of a statistically significant difference, the data from the two arms were pooled
  2. bFor each biomarker, HR represents the hazard ratio for an increase of one unit
  3. cFactors associated with PFS with p < 0.20 in univariate analysis were included in the multivariate model: tumor location, medical history, PIGF on D1 and VEGF-C on D1
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us